Clinical significance of nucleophosmin/B23 and human epidermal growth factor receptor 2/neu expressions in gastric cancers. Issue 7 (13th March 2013)

• Record Type: Journal Article
• Authors: Zhou, Fang; Qiu, Wensheng; Sun, Lingling; Xiang, Jinyu; Sun, Xiaoxiao; Sui, Aihua; Ding, Aiping; Yue, Lu
• Is Part Of: Apmis. Volume 121:Issue 7(2013:Jul.)
• Page Start: 582
• Page End: 591
• Publication Date: 2013-03-13
• Subjects: Pathology -- Periodicals; Microbiology -- Periodicals; Immunology -- Periodicals; 572
• DOI: 10.1111/apm.12043
• Languages: English
• ISSNs: 0903-4641

Abstract

<abstract abstract-type="main" xml:lang="en" id="apm12043-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p>The aim of the study was to investigate the expression levels of 'NPM'/nucleophosmin/B23 and human epidermal growth factor receptor 2 (Her‐2)/neu in gastric cancer (GC) and corresponding non‐malignant tissues, correlation with their clinicopathological parameters and the relationship of nucleophosmin/B23 and Her‐2/neu in the occurrence and development of GC. A total of 131 postoperative patients were examined for nucleophosmin/B23 expression by immuno‐histochemistry and for Her‐2/neu expression by fluorescence <italic>in situ</italic> hybridization with the median follow‐up period of 38 months. The positive expression rates of nucleophosmin (NPM) in neoplastic tissues and adjacent gastric mucosa were 65.6% and 52.7%, respectively. Nucleophosmin/B23 levels were linked to more advanced tumor stages, poor prognosis, and likelihood of recurrence (p < 0.05). The Cox multivariate analysis indicated that the nucleophosmin/B23 expression was an independent indicator for tumor recurrence (p = 0.011). Of the total GC specimens 12.21% were positive for Her‐2/neu, but whose expression was of no correlation with patients' survival. Patients who were positive for Her‐2/neu also had high NPM expression levels (p = 0.0303). The results suggest that nucleophosmin/B23 is a favorable prognostic indicator for GC. But Her‐2/neu has no relationship with the prognosis of GC. The combined clinical significance of nucleophosmin/B23 and Her‐2/neu remains to be further investigated.</p> </abstract>